Avantor (Avantor) Cash And Cash Equivalents : $263 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Avantor Cash And Cash Equivalents?

Avantor's quarterly cash and cash equivalents increased from Jun. 2023 ($236.40 Mil) to Sep. 2023 ($236.90 Mil) and increased from Sep. 2023 ($236.90 Mil) to Dec. 2023 ($262.90 Mil).

Avantor's annual cash and cash equivalents increased from Dec. 2021 ($301.70 Mil) to Dec. 2022 ($372.90 Mil) but then declined from Dec. 2022 ($372.90 Mil) to Dec. 2023 ($262.90 Mil).

Avantor Cash And Cash Equivalents Historical Data

The historical data trend for Avantor's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avantor Cash And Cash Equivalents Chart

Avantor Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

186.70

286.60

301.70

372.90

262.90

Avantor Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															372.90	294.60	236.40	236.90	262.90

Avantor Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Avantor (NYSE:AVTR) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Avantor Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Avantor's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Avantor (Avantor) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Avantor Inc (NYSE:AVTR) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

AVG:Germany

Address

100 Matsonford Road, Suite 200, Building One, Radnor Corporate Center, Radnor, PA, USA, 19087

Website

https://www.avantorsciences.com

Avantor Inc is involved in providing products and services to biopharma, healthcare, education and government, and advanced technologies and applied materials industries. The company's offerings include materials and consumables, equipment and instrumentation and services and specialty procurement. Its brand profile consists of NuSil, RANKEM, POCH, BeneSphera, and Macron Fine Chemicals among others. The firm operates in three geographical segments namely Americas, Europe, and AMEA. It generates a majority of its revenue from the Americas.

Executives

Benoit Gourdier	officer: EVP, Biopharma Production	100 MATSONFORD ROAD, RADNOR PA 19087
Steven W Eck	officer: SVP & Chief Accounting Officer	C/O CSS INDUSTRIES, INC., 450 PLYMOUTH ROAD, SUITE 300, PLYMOUTH MEETING PA 19462
Frederic Vanderhaegen	officer: EVP, Europe	C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Brittany Hankamer	officer: EVP, Chief HR Officer	100 MATSONFORD ROAD, RADNOR PA 19087
R. Brent Jones	officer: EVP, Chief Financial Officer	C/O PALL CORPORATION, 25 HARBOR PARK DRIVE, PORT WASHINGTON NY 11050
Claudius Sokenu	officer: EVP, Chief Legal & Compliance	C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, BLUE BELL PA 19422
Randy Lee Stone	officer: EVP, Proprietary Products	974 CENTRE ROAD, CRP 730, WILMINGTON DE 19805
Christophe Couturier	officer: See Remarks	9 FOURTH AVENUE, C/O OVASCIENCE INC., CAMBRIDGE MA 02451
Gerard Brophy	officer: EVP, Biopharma Production	C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Kitty Sahin	officer: EVP, Strategy&Corp Development	100 MATSONFORD ROAD, RADNOR PA 19087
Thomas A Szlosek	officer: EVP and CFO	HONEYWELL INTERNATIONAL INC., 115 TABOR ROAD, MORRIS PLAINS NJ 07950
Michael Stubblefield	director, officer: President and CEO	C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Rajiv Gupta	director	234 RAVENCLIFF DRIVE, ST DAVIDS PA 19087
Joseph R Massaro	director	5725 DELPHI DRIVE, TROY MI 48098
Mala Murthy	director	C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577